Simon Bailey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9461723/publications.pdf

Version: 2024-02-01

54 papers	4,365 citations	257450 24 h-index	223800 46 g-index
54 all docs	54 docs citations	54 times ranked	5943 citing authors

#	Article	IF	Citations
1	SIOP PODCâ€“adapted treatment guidelines for craniopharyngioma in lowâ€•and middleâ€•income settings. Pediatric Blood and Cancer, 2023, 70, e28493.	1.5	8
2	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology, 2022, 24, 153-165.	1.2	28
3	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	3.7	16
4	Developmental delay and progressive seizures in 2â€•monthâ€•old child with diffuse MRI abnormalities. Brain Pathology, 2022, 32, e13049.	4.1	2
5	Metabolite selection for machine learning in childhood brain tumour classification. NMR in Biomedicine, 2022, 35, e4673.	2.8	7
6	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12
7	LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma. Neuro-Oncology, 2022, 24, i89-i89.	1.2	1
8	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
9	MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse. Neuro-Oncology, 2022, 24, i115-i115.	1.2	0
10	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0
11	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.7	27
12	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Liâ€“Fraumeni syndrome. Leukemia, 2021, 35, 1475-1479.	7.2	17
13	Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics. Neuropathology and Applied Neurobiology, 2021, 47, 736-747.	3.2	9
14	Perioperative corticosteroid use in paediatric neuro-oncology. Child's Nervous System, 2021, 37, 3669-3671.	1.1	1
15	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. The Lancet Child and Adolescent Health, 2020, 4, 865-874.	5.6	48
16	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nature Communications, 2020, 11, 4324.	12.8	75
17	Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a lowâ€•income setting â€” the Blantyre experience. British Journal of Haematology, 2020, 191, e87-e90.	2.5	1
18	Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. Pediatric Blood and Cancer, 2020, 67, e28322.	1.5	17

#	Article	IF	Citations
19	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
20	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326.	7.7	180
21	Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Advances, 2019, 3, 2118-2127.	5.2	23
22	Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. Pediatric Blood and Cancer, 2018, 65, e26841.	1.5	7
23	Application of pattern recognition techniques for classification of pediatric brain tumors by in vivo 3T ¹Hâ€MR spectroscopyâ€"A multiâ€center study. Magnetic Resonance in Medicine, 2018, 79, 2359-2366.	3.0	29
24	Global Challenges in Pediatric Neuro-Oncology. , 2018, , 403-426.		0
25	MBRS-29. IN-VIVO METABOLITE PROFILES FOR THE NON-INVASIVE AND RAPID IDENTIFICATION OF MOLECULAR SUBGROUP IN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i134-i134.	1.2	0
26	â€œThey've got a lot of needs and I don't think they're being met fullyâ€: A qualitative study of the multiâ€professional team approach to the management of children with optic pathway gliomas. Pediatric Blood and Cancer, 2018, 65, e27377.	1.5	6
27	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
28	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenetics and Genomics, 2017, 27, 213-222.	1.5	51
29	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
30	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncology, The, 2017, 18, 958-971.	10.7	384
31	The use of anthracyclines in the treatment of endemic Burkitt lymphoma. British Journal of Haematology, 2017, 177, 984-990.	2.5	16
32	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood and Cancer, 2017, 64, e26737.	1.5	21
33	A framework to develop adapted treatment regimens to manage pediatric cancer in lowâ€and middleâ€income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatric Blood and Cancer, 2017, 64, e26879.	1.5	48
34	A School Passport as Part of a Protocol to Assist Educational Reintegration After Medulloblastoma Treatment in Childhood. Pediatric Blood and Cancer, 2016, 63, 1636-1642.	1.5	11
35	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
36	Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990â€“2013. European Journal of Cancer, 2016, 61, 36-43.	2.8	16

#	Article	IF	Citations
37	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
38	Outcome is unchanged by adding vincristine upfront to the Malawi 28â€day protocol for endemic Burkitt lymphoma. Pediatric Blood and Cancer, 2015, 62, 1929-1934.	1.5	15
39	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	16.8	165
40	SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatric Blood and Cancer, 2015, 62, 553-564.	1.5	50
41	Intracystic interferon therapy in childhood craniopharyngioma: who, when and how?. Clinical Endocrinology, 2015, 82, 29-34.	2.4	13
42	Kaposiâ€™s sarcoma in children: An open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. European Journal of Cancer, 2014, 50, 1472-1481.	2.8	27
43	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
44	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
45	Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathologica, 2013, 126, 943-946.	7.7	28
46	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
47	Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica, 2013, 98, e1-e3.	3.5	9
48	Burkitt's lymphoma. Lancet, The, 2012, 379, 1234-1244.	13.7	486
49	The importance of biopsy following radiological diagnosis of relapsed medulloblastoma. British Journal of Neurosurgery, 2012, 26, 542-544.	0.8	0
50	Central nervous system lesions in Malawian children: identifying the treatable. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 567-569.	1.8	4
51	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica, 2012, 123, 501-513.	7.7	87
52	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 2011, 121, 381-396.	7.7	474
53	Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology, 2011, 29, 1400-1407.	1.6	263
54	Hypercalcemia in Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2009, 31, 424-427.	0.6	46